Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$21.7M
8M shares
52-week range
$2.02 – $22.20
2% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
P/S (TTM)
3.5
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
www.femasys.comNo one on the platform currently holds FEMY.
No tracked institution reports a position in FEMY as of their last filing.
| Execution date | Ratio |
|---|---|
| 2026-06-08 | 1-for-20reverse |
No one on the platform has traded FEMY yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 40.8% | 17.2% | ||||
| Profit Margin % | -812.3% | -976.0% | ||||
| Free Cash Flow Margin % | -837.9% | -953.1% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3M | +3.7% | $-2.28 | $-2.62–$-2.03 | — | 1 |
| 2027 | $9M | +238.2% | $-1.75 | $-2.13–$-1.37 | — | 2 |
| 2028 | $20M | +121.8% | $-1.22 | $-1.76–$-0.51 | — | 3 |
| 2029 | $48M | +142.4% | $-0.17 | $-0.20–$-0.15 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-14 | $-1.31 | $-1.33 | -1.5% |
| 2026-05-08 | $-1.33 | $0.10 | +107.4% |
| 2026-03-26 | $-1.67 | $-1.25 | +24.8% |
| 2025-11-11 | $-2.30 | $-2.00 | +13.0% |
| 2025-08-08 | $-3.27 | $-3.20 | +2.0% |
| 2025-05-08 | $-3.40 | $-4.60 | -35.3% |
| 2025-03-27 | $-3.70 | $-4.60 | -24.3% |
| 2024-11-12 | $-4.00 |
| $-4.80 |
| -20.0% |
| $15M |
| — |
| CRISCuris, Inc. | $1.00 | -8.26% | $2M | — |
| DAREDare Bioscience, Inc. | $0.78 | +4.88% | $12M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$FEMY Do you realize the magnitude of what they(we) have
View on StockTwits ↗
$FEMY i'm beginning to think I own a garbage stock and A lot of it
View on StockTwits ↗
A four-location OB/GYN group just went all-in on Femasys' fertility platform. Femasys (NASDAQ: $FEMY) announced Minnesota Women's Care will adopt FemVue and FemaSeed across all four of its practice locations — a full-scale rollout, not a pilot. The deal lands right after Femasys' August financing, as the company scales its commercial team to drive broader OB/GYN adoption. Multi-site wins like this are the proof points investors watch for early commercial traction. https://prismmarketview.com/companies/femasys-inc/#news
View on StockTwits ↗
$FEMY bag of bollocks this is! FDA announcement nothing happened. It’s just dropping its arse again
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.